Πλοήγηση ανά Θέμα "B Raf kinase"
Αποτελέσματα 1-7 από 7
-
The current role of surgery in the treatment of cardiac metastases from malignant melanoma: An educational presentation
(2021)A 71 year-old male with a history of multiple excisions of an initial Clark’s level V melanoma of the breast followed by combined radiation and interferon treatment, as well as a recurrence, 3 years later, of a BRAF-positive ... -
Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation
(2019)Despite the clinical success of BRAF inhibitors like vemurafenib in treating metastatic melanoma, resistance has emerged through "paradoxical MEK/ERK signaling" where transactivation of one protomer occurs as a result of ... -
Diagnostic value of immunohistochemistry for the detection of the BRAF V600E mutation in colorectal carcinoma
(2016)Purpose: V600E is the most common activating BRAF mutation in colorectal carcinomas (CRCs). It is a crucial biomarker for patient selection and response to targeted therapy with BRAF V600E inhibitors. Previous studies using ... -
HIF-1α in colorectal carcinoma: Review of the literature
(2015)Colorectal cancer (CRC) is the third most common cancer worldwide and despite the abundance of molecular pathways and markers continually being reported, the mortality rates remain high. Hypoxia inducible f actor lalpha ... -
Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population
(2020)Thyroid cancer is a common endocrine malignancy and displays a variety of histological patterns ranging from adenoma to malignant tumors. Molecular diagnostics have given significant insights into the genetic basis of ... -
Mutation profile of KRAS and BRAF genes in patients with colorectal cancer: Association with morphological and prognostic criteria
(2015)KRAS and BRAF mutations are well-recognized molecular alterations during colorectal carcinogenesis, but there is little agreement on their effect on tumor characteristics. Therefore, we aimed to evaluate the distribution ... -
Tumor heterogenicity: Multiple needle biopsies from different lesion sites-key to successful targeted therapy and immunotherapy
(2018)[No abstract available]